Jacobs Levy Equity Management’s Ultragenyx Pharmaceutical RARE Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $11M | Buy |
+303,565
| New | +$11M | 0.04% | 285 |
|
|
2024
Q4 | – | Sell |
-97,960
| Closed | -$5.44M | – | 1027 |
|
|
2024
Q3 | $5.44M | Sell |
97,960
-536,367
| -85% | -$29.8M | 0.02% | 432 |
|
|
2024
Q2 | $26.1M | Sell |
634,327
-53,292
| -8% | -$2.19M | 0.11% | 187 |
|
|
2024
Q1 | $32.1M | Sell |
687,619
-31,359
| -4% | -$1.46M | 0.14% | 158 |
|
|
2023
Q4 | $34.4M | Sell |
718,978
-29,300
| -4% | -$1.4M | 0.17% | 136 |
|
|
2023
Q3 | $26.7M | Buy |
748,278
+143,991
| +24% | +$5.13M | 0.16% | 146 |
|
|
2023
Q2 | $27.9M | Sell |
604,287
-171,488
| -22% | -$7.91M | 0.16% | 157 |
|
|
2023
Q1 | $31.1M | Buy |
775,775
+114,692
| +17% | +$4.6M | 0.19% | 135 |
|
|
2022
Q4 | $30.6M | Buy |
661,083
+440,203
| +199% | +$20.4M | 0.21% | 142 |
|
|
2022
Q3 | $9.15M | Buy |
+220,880
| New | +$9.15M | 0.07% | 269 |
|
|
2022
Q1 | – | Sell |
-2,876
| Closed | -$242K | – | 1073 |
|
|
2021
Q4 | $242K | Buy |
+2,876
| New | +$242K | ﹤0.01% | 912 |
|
|
2020
Q4 | – | Sell |
-11,898
| Closed | -$978K | – | 1079 |
|
|
2020
Q3 | $978K | Sell |
11,898
-14,908
| -56% | -$1.23M | 0.01% | 673 |
|
|
2020
Q2 | $2.1M | Buy |
26,806
+17,029
| +174% | +$1.33M | 0.02% | 527 |
|
|
2020
Q1 | $434K | Buy |
+9,777
| New | +$434K | 0.01% | 774 |
|
|
2018
Q2 | – | Sell |
-4,730
| Closed | -$241K | – | 1083 |
|
|
2018
Q1 | $241K | Buy |
+4,730
| New | +$241K | ﹤0.01% | 897 |
|